{
    "nct_id": "NCT00744978",
    "title": "A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Crossover Trial of Varenicline Tartrate (CP-526,555) in Patients With Mild to Moderate Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2011-10-12",
    "description_brief": "1. Assess the efficacy of varenicline, relative to placebo, on a performance based measure of cognition in patients with mild to moderate Alzheimer's disease\n2. Evaluate the effects of varenicline on clinically relevant measures including attention and executive function, behavior, and clinician rated global change.\n3. Evaluate the safety and tolerability of varenicline, relative to placebo, in patients with mild to moderate Alzheimer's disease\n4. Evaluate the pharmacokinetics of varenicline in patients with mild to moderate Alzheimer's disease.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "preAssignmentDetails": "Each participant was to complete a 3-week placebo run-in period then receive a treatment sequence of either varenicline followed by placebo, or placebo followed by varenicline, separated by a 3-week placebo washout period. Of 92 participants screened, 66 participants were randomized to treatment.",
            "groups": [
                {
                    "id": "FG000",
                    "title": "Varenicline Then Placebo",
                    "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks; then placebo once daily for 1 week followed by placebo BID for 5 weeks."
                },
                {
                    "id": "FG001",
                    "title": "Placebo Then Varenicline",
                    "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks; then varenicline 0.5 mg once daily for 1 week followed by 0.5 mg BID for 1 week followed by 1 mg BID for 4 weeks."
                }
            ],
            "periods": [
                {
                    "title": "Period 1",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "32"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "34"
                                }
                            ]
                        },
                        {
                            "type": "Treated",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "31"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "33"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "26"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "29"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "5"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Lost to Follow-up",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "2"
                                }
                            ]
                        },
                        {
                            "type": "Other",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "2"
                                }
                            ]
                        },
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "4"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "Randomized but not Treated",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "1"
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Placebo Washout",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "26"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "29"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "26"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "29"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Period 2",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "26"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "29"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "26"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "28"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "1"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "1"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Varenicline Then Placebo",
                    "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks; then placebo once daily for 1 week followed by placebo BID for 5 weeks."
                },
                {
                    "id": "BG001",
                    "title": "Placebo Then Varenicline",
                    "description": "Placebo twice a day (BID) initiated with a 2-week titration regimen (Week 1: once a day \\[QD\\]; Week 2: BID), followed by varenicline 1 mg BID initiated with a 2-week titration regimen (Week 1: 0.5 mg QD; Week 2: 0.5 mg BID)."
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "32"
                        },
                        {
                            "groupId": "BG001",
                            "value": "34"
                        },
                        {
                            "groupId": "BG002",
                            "value": "66"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "71.5",
                                            "spread": "8.7"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "73.9",
                                            "spread": "5.8"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "72.7",
                                            "spread": "7.4"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "21"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "21"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "42"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "11"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "13"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "24"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 6",
                    "description": "12-item scale to assess severity of cognitive impairment in AD. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, remembering test instructions, and concentration/distractibility. Total score range from 0-75 with 75 indicating worse cognition.",
                    "populationDescription": "Full analysis set (FAS): all participants who were randomized and took at least 1 dose of randomized study medication. N = number of participants with ADAS-Cog 75 results at Week 6.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "units on scale",
                    "timeFrame": "Week 6",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "53"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "55"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "18.07",
                                            "spread": "0.942"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "18.49",
                                            "spread": "0.939"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo. Analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.3873",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; Type I error rate for primary hypothesis was 5%; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.42",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-1.37",
                            "ciUpperLimit": "0.53"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 3",
                    "description": "12-item scale to assess severity of cognitive impairment in AD. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, remembering test instructions, and concentration/distractibility. Total score range from 0-75 with 75 indicating worse cognition.",
                    "populationDescription": "FAS; N = number of participants with ADAS-Cog 75 results at Week 3.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "units on scale",
                    "timeFrame": "Week 3",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "58"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "54"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "19.87",
                                            "spread": "0.935"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "19.31",
                                            "spread": "0.941"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo. Analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.2465",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.55",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.39",
                            "ciUpperLimit": "1.49"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 3",
                    "description": "11-item scale designed to assess the severity of cognitive impairments in AD subjects. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, and remembering test instructions. Total score range from 0-70 with 70 indicating worse cognition.",
                    "populationDescription": "FAS. N = number of participants with ADAS-Cog 70 results at Week 3.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "units on scale",
                    "timeFrame": "Week 3",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "58"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "54"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "19.60",
                                            "spread": "0.880"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "19.01",
                                            "spread": "0.885"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.2092",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.59",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.33",
                            "ciUpperLimit": "1.50"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 6",
                    "description": "11-item scale designed to assess the severity of cognitive impairments in AD subjects. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, and remembering test instructions. Total score range from 0-70 with 70 indicating worse cognition.",
                    "populationDescription": "FAS. N = number of participants with ADAS-Cog 70 results at Week 6.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "units on scale",
                    "timeFrame": "Week 6",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "53"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "55"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "17.86",
                                            "spread": "0.886"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "18.23",
                                            "spread": "0.884"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.4339",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.37",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-1.30",
                            "ciUpperLimit": "0.56"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Mean Clinical Global Impression - Improvement (CGI-I) Score at Week 6",
                    "description": "CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.",
                    "populationDescription": "FAS; N = number of participants with a CGI-I score at Week 6.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "Week 6",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "54"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "55"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "3.71",
                                            "spread": "0.103"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "3.70",
                                            "spread": "0.102"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo analyzed using a mixed effects linear model with subject (nested within sequence) as a random effect, and stratum, site, period, sequence, and treatment as fixed effects.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.9745",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.00",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.26",
                            "ciUpperLimit": "0.27"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Neuropsychiatric Inventory (NPI) Total Score at Week 3",
                    "description": "Caregiver interview-based rating scale assessing 12 behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, appetite/eating, and sleep. Each symptom score derived by frequency of symptoms \\* severity of symptoms (range 0-12). Total score = sum of symptom scores; range: 0-144 with higher score indicating greater behavioral disturbances.",
                    "populationDescription": "FAS. N = number of participants with a NPI total score at Week 3.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "scores on scale",
                    "timeFrame": "Week 3",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "59"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "54"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.97",
                                            "spread": "0.845"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2.29",
                                            "spread": "0.858"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.2852",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.68",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.57",
                            "ciUpperLimit": "1.92"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Neuropsychiatric Inventory (NPI) Total Score at Week 6",
                    "description": "Caregiver interview-based rating scale assessing 12 behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, appetite/eating, and sleep. Each symptom score derived by frequency of symptoms \\* severity of symptoms (range 0-12). Total score = sum of symptom scores; range: 0-144 with higher score indicating greater behavioral disturbances.",
                    "populationDescription": "FAS. N = number of participants with a NPI total score at Week 6.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "scores on scale",
                    "timeFrame": "Week 6",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "54"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "55"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "3.82",
                                            "spread": "0.857"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2.55",
                                            "spread": "0.855"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.0468",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "1.28",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "0.02",
                            "ciUpperLimit": "2.53"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 1",
                    "description": "Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \\[5000\\]) were excluded as reflecting responses that were abnormally slow.",
                    "populationDescription": "FAS; N = number of participants with a CogState score for Detection at Week 1.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "log10 millisecond",
                    "timeFrame": "Week 1",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "59"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "56"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.65",
                                            "spread": "0.015"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2.64",
                                            "spread": "0.015"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.8811",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.00",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.02",
                            "ciUpperLimit": "0.03"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 3",
                    "description": "Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \\[5000\\]) were excluded as reflecting responses that were abnormally slow.",
                    "populationDescription": "FAS; N = number of participants with a CogState score for Detection at Week 3.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "log10 millisecond",
                    "timeFrame": "Week 3",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "58"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "54"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.65",
                                            "spread": "0.015"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2.63",
                                            "spread": "0.015"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.0830",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.02",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.00",
                            "ciUpperLimit": "0.05"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 6",
                    "description": "Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \\[5000\\]) were excluded as reflecting responses that were abnormally slow.",
                    "populationDescription": "FAS; N = number of participants with a CogState score for Detection at Week 6.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "log10 millisecond",
                    "timeFrame": "Week 6",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "53"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "55"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.64",
                                            "spread": "0.015"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2.65",
                                            "spread": "0.015"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.7226",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.00",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.03",
                            "ciUpperLimit": "0.02"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 1",
                    "description": "Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times.",
                    "populationDescription": "FAS; N = number of participants with a CogState score for Continuous Paired Associate Learning at Week 1.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "errors",
                    "timeFrame": "Week 1",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "59"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "56"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "38.52",
                                            "spread": "2.586"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "40.05",
                                            "spread": "2.626"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Week 1: difference from placebo. Analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.5588",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-1.53",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-6.68",
                            "ciUpperLimit": "3.62"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 3",
                    "description": "Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times.",
                    "populationDescription": "FAS; N = number of participants with a CogState score for Continuous Paired Associate Learning at Week 3.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "errors",
                    "timeFrame": "Week 3",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "58"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "54"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "39.43",
                                            "spread": "2.600"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "43.57",
                                            "spread": "2.656"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.1173",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-4.15",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-9.34",
                            "ciUpperLimit": "1.05"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 6",
                    "description": "Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times.",
                    "populationDescription": "FAS; N = number of participants with a CogState score for Continuous Paired Associate Learning at Week 6.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "errors",
                    "timeFrame": "Week 6",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "53"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "55"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "41.67",
                                            "spread": "2.668"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "42.98",
                                            "spread": "2.641"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.6251",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-1.31",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-6.58",
                            "ciUpperLimit": "3.96"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 1",
                    "description": "Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.",
                    "populationDescription": "FAS; N = number of participants with a CogState score for One Back Working Memory at Week 1.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "arcsine proportion correct",
                    "timeFrame": "Week 1",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "59"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "56"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.94",
                                            "spread": "0.031"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.94",
                                            "spread": "0.031"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.9109",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.00",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.05",
                            "ciUpperLimit": "0.05"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 3",
                    "description": "Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.",
                    "populationDescription": "FAS; N = number of participants with a CogState score for One Back Working Memory at Week 3.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "arcsine proportion correct",
                    "timeFrame": "Week 3",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "58"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "54"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.96",
                                            "spread": "0.031"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.97",
                                            "spread": "0.032"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.6632",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.01",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.06",
                            "ciUpperLimit": "0.04"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 6",
                    "description": "Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.",
                    "populationDescription": "FAS; N = number of participants with a CogState score for One Back Working Memory at Week 6.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "arcsine proportion correct",
                    "timeFrame": "Week 6",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "53"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "55"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.95",
                                            "spread": "0.032"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.96",
                                            "spread": "0.031"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.5450",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.02",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.07",
                            "ciUpperLimit": "0.04"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 1",
                    "description": "Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \\[AD\\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.",
                    "populationDescription": "FAS; N = number of participants with a CogState score for Visual Learning at Week 1.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "arcsine proportion correct",
                    "timeFrame": "Week 1",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "59"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "56"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.83",
                                            "spread": "0.015"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.81",
                                            "spread": "0.016"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.2799",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.02",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.02",
                            "ciUpperLimit": "0.05"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 3",
                    "description": "Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \\[AD\\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.",
                    "populationDescription": "FAS; N = number of participants with a CogState score for Visual Learning at Week 3.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "arcsine proportion correct",
                    "timeFrame": "Week 3",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "58"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "54"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.82",
                                            "spread": "0.016"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.82",
                                            "spread": "0.016"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo aAnalyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.9675",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.00",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.03",
                            "ciUpperLimit": "0.04"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 6",
                    "description": "Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \\[AD\\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.",
                    "populationDescription": "FAS; N = number of participants with a CogState score for Visual Learning at Week 6.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "arcsine proportion correct",
                    "timeFrame": "Week 6",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "53"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "55"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.83",
                                            "spread": "0.016"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.84",
                                            "spread": "0.016"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.5008",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.01",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.05",
                            "ciUpperLimit": "0.02"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 1",
                    "description": "Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \\[5000\\]) were excluded as reflecting responses that were abnormally slow.",
                    "populationDescription": "FAS; N = number of participants with a CogState score for Identification at Week 1.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "log10 millisecond",
                    "timeFrame": "Week 1",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "59"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "56"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.79",
                                            "spread": "0.011"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2.80",
                                            "spread": "0.011"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.2245",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.01",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.03",
                            "ciUpperLimit": "0.01"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 3",
                    "description": "Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \\[5000\\]) were excluded as reflecting responses that were abnormally slow.",
                    "populationDescription": "FAS; N = number of participants with a CogState score for Identification at Week 3.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "log10 millisecond",
                    "timeFrame": "Week 3",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "58"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "54"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.79",
                                            "spread": "0.011"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2.80",
                                            "spread": "0.011"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.4974",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.01",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.03",
                            "ciUpperLimit": "0.01"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 6",
                    "description": "Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \\[5000\\]) were excluded as reflecting responses that were abnormally slow.",
                    "populationDescription": "FAS; N = number of participants with a CogState score for Identification at Week 6.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "log10 millisecond",
                    "timeFrame": "Week 6",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Varenicline",
                            "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "52"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "55"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.79",
                                            "spread": "0.012"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2.79",
                                            "spread": "0.011"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference from placebo analyzed using a mixed effects longitudinal linear model with subject (nested within sequence) as a random effect and fixed effects stratum, site, period, sequence, treatment, week, and treatment by week.",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.8525",
                            "pValueComment": "ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.00",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.02",
                            "ciUpperLimit": "0.02"
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "0",
            "description": "The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Varenicline",
                    "description": "Varenicline 0.5 mg once daily for 1 week followed by 0.5 mg twice daily (BID) for 1 week followed by 1 mg BID for 4 weeks.",
                    "seriousNumAffected": 2,
                    "seriousNumAtRisk": 60,
                    "otherNumAffected": 56,
                    "otherNumAtRisk": 60
                },
                {
                    "id": "EG001",
                    "title": "Placebo",
                    "description": "Placebo once daily for 1 week followed by placebo twice daily (BID) for 5 weeks.",
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 59,
                    "otherNumAffected": 37,
                    "otherNumAtRisk": 59
                }
            ],
            "seriousEvents": [
                {
                    "term": "Asthenia",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Fracture",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Prostate cancer",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "External ear inflammation",
                    "organSystem": "Ear and labyrinth disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Tinnitus",
                    "organSystem": "Ear and labyrinth disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Cataract",
                    "organSystem": "Eye disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Conjunctival haemorrhage",
                    "organSystem": "Eye disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Eye disorder",
                    "organSystem": "Eye disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Abdominal discomfort",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Abdominal pain",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Abdominal pain lower",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Abdominal pain upper",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Constipation",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Diarrhoea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Dry mouth",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Duodenal ulcer",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Dyspepsia",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 4,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Gastric disorder",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Gastritis haemorrhagic",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Inguinal hernia",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Nausea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 17,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Stomatitis",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Vomiting",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 12,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Asthenia",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Fatigue",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Feeling abnormal",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Hunger",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Malaise",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Oedema peripheral",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Pyrexia",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Bronchitis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Nasopharyngitis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 4,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Upper respiratory tract infection",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Urinary tract infection",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Fall",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Scratch",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Skin laceration",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Alanine aminotransferase increased",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Aspartate aminotransferase increased",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Urine analysis abnormal",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Weight decreased",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "White blood cells urine positive",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Decreased appetite",
                    "organSystem": "Metabolism and nutrition disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 13,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 6,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Hypercholesterolaemia",
                    "organSystem": "Metabolism and nutrition disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Hypokalaemia",
                    "organSystem": "Metabolism and nutrition disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Arthralgia",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Arthritis",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Back pain",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Muscle spasms",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Musculoskeletal pain",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Myalgia",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Osteoporosis",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Pain in extremity",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Metastases to spine",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Dementia Alzheimer's type",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Dizziness",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 8,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Headache",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 7,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 4,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Intention tremor",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Lethargy",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Paraesthesia",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Somnolence",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Anxiety",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Depressed mood",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Depression",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Insomnia",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Sleep disorder",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Renal impairment",
                    "organSystem": "Renal and urinary disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Cough",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Epistaxis",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Hiccups",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Oropharyngeal discomfort",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Productive cough",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Dermatitis",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Dermatitis contact",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Ecchymosis",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Erythema nodosum",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Hyperhidrosis",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Pruritus",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Rash pruritic",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Skin irritation",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Hypertension",
                    "organSystem": "Vascular disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 59
                        }
                    ]
                },
                {
                    "term": "Intermittent claudication",
                    "organSystem": "Vascular disorders",
                    "sourceVocabulary": "MedDRA 13.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 60
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 59
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "OTHER",
                "restrictiveAgreement": true,
                "otherDetails": "Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."
            },
            "pointOfContact": {
                "title": "Pfizer ClinicalTrials.gov Call Center",
                "organization": "Pfizer, Inc.",
                "email": "ClinicalTrials.gov_Inquiries@pfizer.com",
                "phone": "1-800-718-1021"
            }
        }
    },
    "target_category": "cognitive enhancer",
    "drug": [
        "varenicline tartrate (CP-526,555)",
        "varenicline"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests varenicline for effects on cognition (performance-based cognitive measures, attention, executive function, global change) in mild\u2013moderate AD, indicating a symptomatic/cognitive-enhancing intent rather than targeting core AD pathology (amyloid or tau).",
        "Support: Varenicline is a small\u2011molecule nicotinic receptor agonist/partial agonist (\u03b14\u03b22 nAChR; activity at \u03b17 also reported), a mechanism aimed at modulating cholinergic neurotransmission and cognition rather than directly modifying AD pathology. \ue200cite\ue202turn0search3\ue202turn0search0\ue201",
        "Act: Extracted details \u2014 intervention: varenicline tartrate (CP\u2011526,555), comparator: placebo, endpoints: cognition (ADAS\u2011Cog/attention/executive function), safety/tolerability, PK. The drug is an orally active small molecule developed/used as a smoking\u2011cessation agent (Chantix) and studied here for symptomatic cognitive effects. \ue200cite\ue202turn0search6\ue202turn0search4\ue201",
        "Reflect: This matches the category \"cognitive enhancer\" (improvement of cognitive performance/attention/executive function) rather than a disease\u2011targeted biologic or small molecule aimed at amyloid/tau. The Phase 2 crossover AD trial you cited (same/similar title) found no cognitive benefit and reported tolerability/AE data \u2014 consistent with a symptomatic cognitive\u2011enhancer trial design. \ue200cite\ue202turn0search4\ue202turn0search2\ue201",
        "Web search results used: PubMed pharmacology/profile of varenicline (partial agonist at \u03b14\u03b22/\u03b17). \ue200cite\ue202turn0search3\ue202turn0search0\ue201; Phase II crossover trial in mild\u2013moderate AD (reported results, no cognitive benefit). \ue200cite\ue202turn0search4\ue201; clinical context/summary (Alzforum). \ue200cite\ue202turn0search2\ue201; varenicline clinical program/approval for smoking cessation (supporting small\u2011molecule classification). \ue200cite\ue202turn0search6\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The intervention is varenicline (CP-526,555), a small\u2011molecule nicotinic acetylcholine receptor ligand with partial agonist activity at \u03b14\u03b22 (and activity at \u03b17/other nAChR subtypes). The trial tests symptomatic cognitive enhancement (attention/executive function, ADAS\u2011Cog) rather than targeting core AD pathology (amyloid or tau), so the biological focus is modulation of neurotransmitter receptors. \ue200cite\ue202turn0search2\ue202turn0search0\ue202turn0search7\ue201",
        "Act: Extracted details \u2014 drug: varenicline tartrate (CP\u2011526,555; marketed as CHANTIX); design: Phase 2 multicenter double\u2011blind placebo\u2011controlled crossover in mild\u2013moderate AD; endpoints: cognition (ADAS\u2011Cog), attention/executive function, behavior, safety/PK. The trial specifically evaluated varenicline's nAChR pharmacology as a cognitive enhancer. \ue200cite\ue202turn0search4\ue202turn0search1\ue202turn0search5\ue201",
        "Reflect: Classification \u2014 CADRO category D) Neurotransmitter Receptors. Varenicline acts on neuronal nicotinic acetylcholine receptors (\u03b14\u03b22 predominant, with \u03b17/\u03b16 interactions reported) which places the trial within neurotransmitter\u2011receptor\u2013directed symptomatic cognitive enhancement rather than amyloid/tau or multi\u2011target disease modification. The Phase 2 study reported no significant cognitive benefit versus placebo, consistent with a symptomatic (receptor\u2011modulating) trial rather than a disease\u2011modifying mechanism. \ue200cite\ue202turn0search0\ue202turn0search2\ue202turn0search1\ue201",
        "Web search results used (key sources): PubMed pharmacology/mechanism studies describing varenicline as \u03b14\u03b22 partial agonist and \u03b17 activity (Mihalak et al., Mol Pharmacol; Mol Pharmacol/other pharmacology reviews). \ue200cite\ue202turn0search0\ue202turn0search2\ue202turn0search6\ue201; Phase II crossover clinical trial report in mild\u2011to\u2011moderate AD (trial results: no significant ADAS\u2011Cog benefit). \ue200cite\ue202turn0search1\ue202turn0search4\ue201; Pfizer/CHANTIX clinical pharmacology page summarizing high affinity/selectivity for \u03b14\u03b22 nAChRs. \ue200cite\ue202turn0search7\ue201"
    ]
}